Longitudinal analysis of genomic mutations in SARS-CoV-2 isolates from persistent COVID-19 patient
Hiroki Futatsusako,
Rina Hashimoto,
Masaki Yamamoto,
Jumpei Ito,
Yasufumi Matsumura,
Hajime Yoshifuji,
Kotaro Shirakawa,
Akifumi Takaori-Kondo,
Kei Sato,
Miki Nagao,
Kazuo Takayama
Affiliations
Hiroki Futatsusako
Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 6068507, Japan
Rina Hashimoto
Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 6068507, Japan
Masaki Yamamoto
Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan
Jumpei Ito
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo 1138654, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan
Yasufumi Matsumura
Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan
Hajime Yoshifuji
Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan
Kotaro Shirakawa
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan
Akifumi Takaori-Kondo
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan
Kei Sato
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo 1138654, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa 2770882, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 8600811, Japan; CREST, Japan Science and Technology Agency, Kawaguchi 3320012, Japan
Miki Nagao
Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan; Corresponding author
Kazuo Takayama
Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 6068507, Japan; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo 1000004, Japan; Corresponding author
Summary: A primary reason for the ongoing spread of coronavirus disease 2019 (COVID-19) is the continuous acquisition of mutations by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the mechanism of acquiring mutations is not fully understood. In this study, we isolated SARS-CoV-2 from an immunocompromized patient persistently infected with Omicron strain BF.5 for approximately 4 months to analyze its genome and evaluate drug resistance. Although the patient was administered the antiviral drug remdesivir (RDV), there were no acquired mutations in RDV binding site, and all isolates exhibited susceptibility to RDV. Notably, upon analyzing the S protein sequence of the day 119 isolate, we identified mutations acquired by mutant strains emerging from the BF.5 variant, suggesting that viral genome analysis in persistent COVID-19 patients may be useful in predicting viral evolution. These results suggest mutations in SARS-CoV-2 are acquired during long-term viral replication rather than in response to antiviral drugs.
